Literature DB >> 21496480

Peripheral immune contributions to the maintenance of central glial activation underlying neuropathic pain.

Peter M Grace1, Paul E Rolan, Mark R Hutchinson.   

Abstract

Recent evidence implicates an adaptive immune response in the central nervous system (CNS) mechanisms of neuropathic pain. This review identifies how neuropathic pain alters CNS immune privilege to facilitate T cell infiltration. Once in the CNS, T cells may interact with the local antigen presenting cells, microglia, via the major histocompatibility complex and the costimulatory molecules CD40 and B7. In this way, T cells may contribute to the maintenance of neuropathic pain through pro-inflammatory interactions with microglia and by facilitating the activation of astrocytes in the spinal dorsal horn. Based on the evidence presented in this review, we suggest that this bidirectional, pro-inflammatory system of neurons, glia and T cells in neuropathic pain should be renamed the pentapartite synapse, and identifies the latest member as a potential disease-modifying therapeutic target.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21496480     DOI: 10.1016/j.bbi.2011.04.003

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  53 in total

Review 1.  Opioid-induced central immune signaling: implications for opioid analgesia.

Authors:  Peter M Grace; Steven F Maier; Linda R Watkins
Journal:  Headache       Date:  2015-03-31       Impact factor: 5.887

Review 2.  Toll-like receptors in chronic pain.

Authors:  Lauren Nicotra; Lisa C Loram; Linda R Watkins; Mark R Hutchinson
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

Review 3.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

4.  H2 Treatment Attenuated Pain Behavior and Cytokine Release Through the HO-1/CO Pathway in a Rat Model of Neuropathic Pain.

Authors:  Yajun Chen; Hongguang Chen; Keliang Xie; Lingling Liu; Yuan Li; Yonghao Yu; Guolin Wang
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

Review 5.  Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity.

Authors:  Dimitris N Xanthos; Jürgen Sandkühler
Journal:  Nat Rev Neurosci       Date:  2013-11-27       Impact factor: 34.870

6.  The prostaglandin E2 receptor EP3 controls CC-chemokine ligand 2-mediated neuropathic pain induced by mechanical nerve damage.

Authors:  Elsa-Marie Treutlein; Katharina Kern; Andreas Weigert; Neda Tarighi; Claus-Dieter Schuh; Rolf M Nüsing; Yannick Schreiber; Nerea Ferreirós; Bernhard Brüne; Gerd Geisslinger; Sandra Pierre; Klaus Scholich
Journal:  J Biol Chem       Date:  2018-05-11       Impact factor: 5.157

7.  Prior exposure to repeated morphine potentiates mechanical allodynia induced by peripheral inflammation and neuropathy.

Authors:  Lisa C Loram; Peter M Grace; Keith A Strand; Frederick R Taylor; Amanda Ellis; Debra Berkelhammer; Melissa Bowlin; Bryce Skarda; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2012-08-10       Impact factor: 7.217

Review 8.  Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain.

Authors:  Paola Sacerdote; Silvia Franchi; Sarah Moretti; Mara Castelli; Patrizia Procacci; Valerio Magnaghi; Alberto E Panerai
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-16       Impact factor: 4.147

Review 9.  Pathological pain and the neuroimmune interface.

Authors:  Peter M Grace; Mark R Hutchinson; Steven F Maier; Linda R Watkins
Journal:  Nat Rev Immunol       Date:  2014-02-28       Impact factor: 53.106

10.  GPR183-Oxysterol Axis in Spinal Cord Contributes to Neuropathic Pain.

Authors:  Fatima Kasbi-Chadli; Morgan Treguier; François Briand; Thierry Sulpice; Khadija Ouguerram
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.